AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31493324 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with adults with SMI and diabetes, their relatives and friends, and health care staff.
Number of subjects: 0
Study 31493324 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of electronic primary care health records from the Clinical Practice Research Datalink (CPRD GOLD).
Number of subjects: 0
Study 31493324 — intervention group
Group type: EXPERIMENTAL
Intervention: Merging findings from both qualitative interviews and health records analysis.
Number of subjects: 0
Study 31493324 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for interventions and services developed through co-design workshops.
Number of subjects: 0
Study 31493591 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Sleep Apnea (SA)
Number of subjects: 553
Study 31493591 — intervention group
Group type: COMPARATOR
Intervention: Nonsevere Sleep Apnea (SA)
Number of subjects: 553
Study 31493591 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both severe and nonsevere SA)
Number of subjects: 553
Study 31494135 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary single, fully covered self-expanding metal stent (FCSEMS) placement with scheduled removal at 10 to 12 months.
Number of subjects: 118
Study 31494181 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX × 6 cycles, followed by radiation therapy (50 Gy in 25 fractions) concurrent with fixed-dose rate gemcitabine (1 g/m2)
Number of subjects: 25
Study 31494181 — intervention group
Group type: EXPERIMENTAL
Intervention: Resected patients (all R0)
Number of subjects: 25
Study 31494181 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 25
Study 31494295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal short-chain fatty acids during pregnancy
Number of subjects: 0
Study 31494295 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31494512 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful control
Number of subjects: 105
Study 31494512 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional control
Number of subjects: 105
Study 31494512 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control
Number of subjects: 105
Study 31494512 — intervention group
Group type: COMPARATOR
Intervention: Behaviorally-indexed child anxiety severity
Number of subjects: 105
Study 31495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoliotic deformity observed in patients with Friedreich ataxia
Number of subjects: 66
Study 31495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Cobb angle measurement
Number of subjects: 66
Study 31495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperkyphosis measurement
Number of subjects: 66
Study 31495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior misalignment measurement
Number of subjects: 66
Study 31495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (arthrodesis)
Number of subjects: 66
Study 31495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Cobb angle with FA severity scores
Number of subjects: 66
Study 31495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior fusion surgery
Number of subjects: 66
Study 31495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of ambulation and spinal surgery
Number of subjects: 66
Study 31495595 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM booster dose
Number of subjects: 701
Study 31496362 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-minute walking test (6MWT) for pwMS
Number of subjects: 49
Study 31496362 — intervention group
Group type: COMPARATOR
Intervention: Six-minute walking test (6MWT) for HC
Number of subjects: 49
Study 31496462 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral to internet-delivered treatment
Number of subjects: 255
Study 31496462 — intervention group
Group type: COMPARATOR
Intervention: Clinician-referral to face-to-face treatment
Number of subjects: 255
Study 31496644 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mL (40 μg) intravitreal dexamethasone solution
Number of subjects: 27
Study 31496644 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mL (120 μg) intravitreal dexamethasone solution
Number of subjects: 27
Study 31496644 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mL (200 μg) intravitreal dexamethasone solution
Number of subjects: 27
Study 31496644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone solution
Number of subjects: 27
Study 31496994 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate Loading followed by High Carbohydrate Intake during Prolonged Physical Exercise
Number of subjects: 0
Study 31496994 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31497072 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Number of subjects: 187
Study 31497072 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific taping (Control)
Number of subjects: 187
Study 31498135 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb (UL) robotic motor assessment protocol
Number of subjects: 69
Study 31498564 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily (D3-32)
Number of subjects: 2
Study 31498564 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg single oral doses (D1 and D31)
Number of subjects: 2
Study 31499373 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phase treatment
Number of subjects: 9898
Study 31499518 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation
Number of subjects: 440
Study 31499518 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP first discontinuation
Number of subjects: 440
Study 31499518 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP final discontinuation
Number of subjects: 440
Study 31499518 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV incidence
Number of subjects: 440
Study 31500448 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE/PASP
Number of subjects: 52
Study 31500448 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE/PASP cutoff of 0.31 mm/mm Hg
Number of subjects: 52
Study 31500448 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPSE/PASP, fractional area change/mean pulmonary artery pressure, RV area change/end-systolic area, stroke volume/end-systolic area
Number of subjects: 52
Study 31500448 — intervention group
Group type: COMPARATOR
Intervention: TAPSE/pulmonary artery acceleration time
Number of subjects: 52
Study 31500552 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia via hyperventilation
Number of subjects: 12
Study 31500552 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 31500586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab in combination with irinotecan and fluorouracil
Number of subjects: 34
Study 31500595 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib in combination with radical (chemo-)radiotherapy
Number of subjects: 0
Study 31500595 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib in combination with radical (chemo-)radiotherapy and concurrent low dose cisplatin
Number of subjects: 0
Study 31500595 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study 31500607 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Bronchitis (CB)
Number of subjects: 606
Study 31500607 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema (EM)
Number of subjects: 606
Study 31500607 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of symptoms during the 24-h day (CB and EM)
Number of subjects: 606
Study 31500607 — intervention group
Group type: COMPARATOR
Intervention: Night-time symptoms (CB vs EM)
Number of subjects: 606
Study 31501119 — intervention group
Group type: EXPERIMENTAL
Intervention: Retired professional footballers
Number of subjects: 572
Study 31501119 — intervention group
Group type: COMPARATOR
Intervention: General population controls
Number of subjects: 572
Study 31501123 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic guidance (RG)
Number of subjects: 0
Study 31501123 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation (NV)
Number of subjects: 0
Study 31501123 — intervention group
Group type: COMPARATOR
Intervention: Freehand (FH) surgery
Number of subjects: 0
Study 31501123 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 0
Study 31501123 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic medication use
Number of subjects: 0
Study 31501123 — intervention group
Group type: EXPERIMENTAL
Intervention: Work status
Number of subjects: 0
Study 31501122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerogenic dendritic cells (tolDC) administered via intradermal injection
Number of subjects: 0
Study 31501122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerogenic dendritic cells (tolDC) administered via intranodal injection
Number of subjects: 0
Study 31501122 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolerogenic dendritic cells (tolDC)
Number of subjects: 0
Study 31501130 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome (PRO) measure to assess financial toxicity (FT) in cancer patients
Number of subjects: 0
Study 31501132 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily screening for readiness to discontinue MV
Number of subjects: 1500
Study 31501132 — intervention group
Group type: EXPERIMENTAL
Intervention: Modes of MV used before initial discontinuation attempts
Number of subjects: 1500
Study 31501132 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning and spontaneous breathing trial (SBT) protocols
Number of subjects: 1500
Study 31501132 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT techniques
Number of subjects: 1500
Study 31501132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation and mobilisation practices to facilitate weaning and discontinuation
Number of subjects: 1500
Study 31501132 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT outcome (failure vs success)
Number of subjects: 1500
Study 31501132 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of SBT (early vs later in ICU stay)
Number of subjects: 1500
Study 31501132 — intervention group
Group type: EXPERIMENTAL
Intervention: Different SBT techniques and humidification strategies
Number of subjects: 1500
Study 31501599 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-corrected hematopoietic stem cells
Number of subjects: 0
Study 31501600 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory feedback restoration in leg amputees
Number of subjects: 0
Study 31501975 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (BoNT-A) treatment
Number of subjects: 100
Study 31501989 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual planning using customized surgical devices (VP3D)
Number of subjects: 30
Study 31501989 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (CS)
Number of subjects: 30
Study 31502117 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprutumab ixadotin (0.1-1.3 mg/kg, administered intravenously on day 1 of every 21-day cycle)
Number of subjects: 20
Study 31502117 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprutumab ixadotin
Number of subjects: 20
Study 31502238 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management support provided by trained respiratory educators
Number of subjects: 54
Study 31502330 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) assessment using multislice computed tomography before AF ablation
Number of subjects: 3464
Study 31502330 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior thromboembolism (TE) history
Number of subjects: 3464
Study 31502330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower creatinine clearance (CCr)
Number of subjects: 3464
Study 31502400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib at the pediatric maximum tolerated dose of 12 mg/m²
Number of subjects: 7
Study 31502400 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 7
Study 31502421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab SC 40 mg (bodyweight <40 kg) or 100 mg (≥40 kg) every 4 weeks for 12 weeks
Number of subjects: 36
Study 31502421 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab SC 40 mg or 100 mg
Number of subjects: 36
Study 31502485 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NAb titers (<1:5)
Number of subjects: 0
Study 31502936 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 0
Study 31502936 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-statin users)
Number of subjects: 0
Study 31503017 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (cases 1-25)
Number of subjects: 502
Study 31503017 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (cases 26-65)
Number of subjects: 502
Study 31503017 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (cases 66-88)
Number of subjects: 502
Study 31503017 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (cases 89-125)
Number of subjects: 502
Study 31503017 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy
Number of subjects: 502
Study 31503159 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeroderma pigmentosum females
Number of subjects: 60
Study 31504095 — intervention group
Group type: EXPERIMENTAL
Intervention: Norovirus infection
Number of subjects: 52
Study 31504107 — intervention group
Group type: EXPERIMENTAL
Intervention: WHRadjBMI GRS
Number of subjects: 9895
Study 31504107 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically instrumented 1-SD increase in WHRadjBMI
Number of subjects: 9895
Study 31504335 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV viremia (detected CMV DNA, median plasma viral load 498 IU/mL, IQR 259-2390)
Number of subjects: 111
Study 31504335 — intervention group
Group type: COMPARATOR
Intervention: No CMV viremia (not detected CMV DNA)
Number of subjects: 111
Study 31504342 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot Medroxyprogesterone Acetate (DMPA) 150 mg intramuscular injection
Number of subjects: 42
Study 31504342 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (not specified)
Number of subjects: 42
Study 31504405 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of minimum lumen area (MLA) <3.5 mm2
Number of subjects: 1003
Study 31504405 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of fibrous cap thickness (FCT) <75 µm
Number of subjects: 1003
Study 31504405 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of lipid arc circumferential extension >180°
Number of subjects: 1003
Study 31504405 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of OCT-defined macrophages
Number of subjects: 1003
Study 31504405 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presence of the four OCT criteria in the same plaque
Number of subjects: 1003
Study 31504674 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination (presence of a scar or vaccination history)
Number of subjects: 3453
Study 31504674 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated participants
Number of subjects: 3453
Study 31504882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing e-cigarette for 7 days followed by 6 days of abstinence
Number of subjects: 30
Study 31504985 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy CT (DECT)
Number of subjects: 89
Study 31504985 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical+serum urate subset
Number of subjects: 89
Study 31504985 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical-only subset
Number of subjects: 89
Study 31504985 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical subset
Number of subjects: 89
Study 31504985 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical+serum urate subset with DECT
Number of subjects: 89
Study 31505615 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset left bundle branch block (LBBB) at discharge
Number of subjects: 1179
Study 31506079 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessment at 12 months using the ages and stages questionnaire (ASQ)
Number of subjects: 150
Study 31506079 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessment at 24 months using the Bayley-III test
Number of subjects: 150
Study 31506080 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel FSHD functional composite COA made up of 18 evaluator-administered motor tasks in the domains of shoulder/arm, hand, core/abdominal, leg, and balance function
Number of subjects: 220
Study 31506080 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical impedance myography as a novel muscle quality biomarker
Number of subjects: 220
Study 31506080 — intervention group
Group type: EXPERIMENTAL
Intervention: Domain 1 of the Motor Function Measure
Number of subjects: 220
Study 31506080 — intervention group
Group type: EXPERIMENTAL
Intervention: Reachable workspace
Number of subjects: 220
Study 31506080 — intervention group
Group type: EXPERIMENTAL
Intervention: Orofacial strength using the Iowa Oral Performance Instrument
Number of subjects: 220
Study 31506080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean muscle mass using dual-energy X-ray absorptiometry (DEXA)
Number of subjects: 220
Study 31506080 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength as measured by quantitative myometry and manual muscle testing
Number of subjects: 220
Study 31506080 — intervention group
Group type: EXPERIMENTAL
Intervention: FSHD Health Index and other patient-reported outcomes
Number of subjects: 220
Study 31506084 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine consumption
Number of subjects: 720
Study 31506084 — intervention group
Group type: EXPERIMENTAL
Intervention: Total alcohol consumption
Number of subjects: 720
Study 31506084 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoking status
Number of subjects: 720
Study 31506084 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer and spirit consumption
Number of subjects: 720
Study 31506182 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation
Number of subjects: 26
Study 31506337 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen delivery systems
Number of subjects: 10
Study 31506337 — intervention group
Group type: EXPERIMENTAL
Intervention: High oxygen flows
Number of subjects: 10
Study 31506337 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal tidal volume breathing
Number of subjects: 10
Study 31506385 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib (specific dosage and duration not provided)
Number of subjects: 27
Study 31506387 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T) 0.3 mg/kg once every 6 weeks for two cycles
Number of subjects: 339
Study 31506387 — intervention group
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T)
Number of subjects: 339
Study 31507322 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 0
Study 31507322 — intervention group
Group type: COMPARATOR
Intervention: Other Atypical Antipsychotics (AAPs)
Number of subjects: 0
Study 31507641 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (add-on maintenance therapy)
Number of subjects: 34
Study 31508232 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education intervention (three educational sessions over a six-week period)
Number of subjects: 46
Study 31508232 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular dental visits
Number of subjects: 46
Study 31508483 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 1604
Study 31508483 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal dysfunction (RD)
Number of subjects: 1604
Study 31508483 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia in patients with NYHA class III-IV
Number of subjects: 1604
Study 31508518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (50 mg/kg p.o daily for three weeks)
Number of subjects: 0
Study 31509537 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRe monitoring
Number of subjects: 30
Study 31509667 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-Edited Stem Cells
Number of subjects: 1
Study 31509815 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST-LIFE arrays (longitudinal intrafascicular arrays and fascicular cuff electrodes) implanted in sensory fascicles
Number of subjects: 4
Study 31509815 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST-LIFE arrays (longitudinal intrafascicular arrays and fascicular cuff electrodes) implanted in motor fascicles
Number of subjects: 4
Study 31509815 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST-LIFE arrays (longitudinal intrafascicular arrays and fascicular cuff electrodes)
Number of subjects: 4
Study 31510768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8380
Study 31510768 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8380
Study 31510768 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestion reduction
Number of subjects: 8380
Study 31510768 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination signs of congestion
Number of subjects: 8380
Study 31510769 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal bleeding
Number of subjects: 27395
Study 31510769 — intervention group
Group type: EXPERIMENTAL
Intervention: Genitourinary bleeding
Number of subjects: 27395
Study 31510769 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary bleeding
Number of subjects: 27395
Study 31510769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongastrointestinal, nongenitourinary bleeding
Number of subjects: 27395
Study 31510865 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel sequencing technology using molecular inversion probes for cell-free DNA screening
Number of subjects: 1414
Study 31510897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-stroke group
Number of subjects: 10
Study 31510897 — intervention group
Group type: COMPARATOR
Intervention: Stroke-only group
Number of subjects: 10
Study 31510897 — intervention group
Group type: COMPARATOR
Intervention: Cancer-only group
Number of subjects: 10